⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
NKTR News
Nektar Therapeutics
Nektar Announces Publication in The Lancet of Positive Phase 2b REZOLVE-AD 16-Week Induction Results of Rezpegaldesleukin in Moderate-to-Severe Atopic Dermatitis
prnewswire.com
NKTR
Bronstein, Gewirtz & Grossman, LLC Encourages Nektar Therapeutics (NKTR) Shareholders to Inquire about Securities Investigation
accessnewswire.com
NKTR
Bronstein, Gewirtz & Grossman, LLC Is Investigating Nektar Therapeutics (NKTR) And Encourages Shareholders to Connect
accessnewswire.com
NKTR
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Nektar Therapeutics (NKTR) And Encourages Shareholders to Reach Out
accessnewswire.com
NKTR
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Nektar Therapeutics (NKTR) and Encourages Investors to Learn More About the Investigation
accessnewswire.com
NKTR
Form 8-K
sec.gov
NKTR
Nektar Therapeutics Announces Second Quarter 2026 Financial Results
prnewswire.com
NKTR
Nektar Therapeutics (NKTR) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation
accessnewswire.com
NKTR
Bronstein, Gewirtz & Grossman, LLC Is Investigating Nektar Therapeutics (NKTR) And Encourages Investors to Connect
accessnewswire.com
NKTR
Kuehn Law Encourages Investors of Nektar Therapeutics to Contact Law Firm
prnewswire.com
NKTR